Bioventus (BVS) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 15% year-over-year to $139 million, marking the fourth consecutive quarter of double-digit organic growth.

• Raised full-year revenue guidance to the high end of previous expectations, reflecting strong execution across all business segments.

• Announced divestiture of Advanced Rehabilitation Business for $25 million plus up to $20 million in earnouts, expected to close by early 2025.

• Net loss from continuing operations narrowed to $5.4 million in Q3, with improved profitability and cash flow.

• Focused on accelerating revenue growth, improving profitability, and enhancing liquidity.

Financial highlights

• Q3 revenue reached $139 million, up 15% year-over-year, with U.S. sales up 15.7% and international sales up 10.2%.

• Adjusted EBITDA was $23.6 million, up 8% from prior year; year-to-date Adjusted EBITDA up 21%.

• Adjusted gross margin was 74.7%, nearly flat year-over-year; GAAP gross margin improved to 67.3%.

• Adjusted net income increased 10% to $5 million; adjusted EPS for Q3 was $0.06.

• Ended Q3 with $43 million in cash, $384 million in debt, and $15 million drawn on the revolver.

Outlook and guidance

• Full-year net sales guidance raised to $562–$567 million, reflecting nearly 13% organic growth.

• Adjusted EPS guidance increased to $0.40–$0.42; Adjusted EBITDA guidance unchanged at $104–$107 million.

• Expect to end the year with zero balance on the revolver and double-digit cash flow from operations in Q4.

• Project net leverage ratio below 3x during 2025.

• Management expects current cash, operating cash flows, and credit facility access to be sufficient for at least 12 months.